Nature Reviews Rheumatology最新文献_第10页

Proposals for the rheumatological use of JAK inhibitors 关于在风湿病中使用 JAK 抑制剂的建议。

IF 33.7 1区医学

Nature Reviews Rheumatology Pub Date : 2024-01-12 DOI: 10.1038/s41584-023-01068-3

Francesco Ciccia, Roberto Caporali

引用次数: 0

S100A4 inhibition targets fibrosis in SSc 抑制S100A4可抑制SSc的纤维化

IF 33.7 1区医学

Nature Reviews Rheumatology Pub Date : 2024-01-11 DOI: 10.1038/s41584-024-01080-1

Jessica McHugh

引用次数: 0

Recent advances and evolving concepts in Still’s disease 斯蒂尔病的最新进展和不断演变的概念

IF 33.7 1区医学

Nature Reviews Rheumatology Pub Date : 2024-01-11 DOI: 10.1038/s41584-023-01065-6

Piero Ruscitti, Luca Cantarini, Peter A. Nigrovic, Dennis McGonagle, Roberto Giacomelli

{"title":"Recent advances and evolving concepts in Still’s disease","authors":"Piero Ruscitti, Luca Cantarini, Peter A. Nigrovic, Dennis McGonagle, Roberto Giacomelli","doi":"10.1038/s41584-023-01065-6","DOIUrl":"10.1038/s41584-023-01065-6","url":null,"abstract":"Still’s disease is a rare inflammatory syndrome that encompasses systemic juvenile idiopathic arthritis and adult-onset Still’s disease, both of which can exhibit life-threatening complications, including macrophage activation syndrome (MAS), a secondary form of haemophagocytic lymphohistiocytosis. Genetic insights into Still’s disease involve both HLA and non-HLA susceptibility genes, suggesting the involvement of adaptive immune cell-mediated immunity. At the same time, phenotypic evidence indicates the involvement of autoinflammatory processes. Evidence also implicates the type I interferon signature, mechanistic target of rapamycin complex 1 signalling and ferritin in the pathogenesis of Still’s disease and MAS. Pathological entities associated with Still’s disease include lung disease that could be associated with biologic DMARDs and with the occurrence of MAS. Historically, monophasic, recurrent and persistent Still’s disease courses were recognized. Newer proposals of alternative Still’s disease clusters could enable better dissection of clinical heterogeneity on the basis of immune cell profiles that could represent diverse endotypes or phases of disease activity. Therapeutically, data on IL-1 and IL-6 antagonism and Janus kinase inhibition suggest the importance of early administration in Still’s disease. Furthermore, there is evidence that patients who develop MAS can be treated with IFNγ antagonism. Despite these developments, unmet needs remain that can form the basis for the design of future studies leading to improvement of disease management. In this Review, the authors describe shared pathophysiology of systemic juvenile idiopathic arthritis and adult-onset Still’s disease and their life-threatening complication, macrophage activation syndrome. Therapeutic developments now enable the targeting of multiple pathways in these conditions, and evidence suggests that early use of DMARDs has the potential to prevent chronic disease.","PeriodicalId":18810,"journal":{"name":"Nature Reviews Rheumatology","volume":null,"pages":null},"PeriodicalIF":33.7,"publicationDate":"2024-01-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139419922","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

B cells guide rituximab use in AAV remission B 细胞指导利妥昔单抗在 AAV 缓解期的使用

IF 33.7 1区医学

Nature Reviews Rheumatology Pub Date : 2024-01-11 DOI: 10.1038/s41584-024-01078-9

Sarah Onuora

引用次数: 0

Author Correction: New genes, pathways and therapeutic targets in autoinflammatory diseases 作者更正：自身炎症性疾病的新基因、途径和治疗靶点。

IF 33.7 1区医学

Nature Reviews Rheumatology Pub Date : 2024-01-08 DOI: 10.1038/s41584-024-01075-y

Riccardo Papa, Marco Gattorno

引用次数: 0

The rise of precision cellular therapies 精准细胞疗法的兴起

IF 33.7 1区医学

Nature Reviews Rheumatology Pub Date : 2024-01-08 DOI: 10.1038/s41584-023-01073-6

Maximilian F. Konig

引用次数: 0

Exploring the latest advances in axial spondyloarthritis management 探索轴性脊柱关节炎治疗的最新进展

IF 33.7 1区医学

Nature Reviews Rheumatology Pub Date : 2024-01-08 DOI: 10.1038/s41584-023-01072-7

Diego Benavent, Victoria Navarro-Compán

引用次数: 0

Advances in the treatment of polymyalgia rheumatica and giant cell arteritis 多发性风湿痛和巨细胞动脉炎的治疗进展

IF 33.7 1区医学

Nature Reviews Rheumatology Pub Date : 2024-01-08 DOI: 10.1038/s41584-023-01069-2

Lindsay Lally, Robert Spiera

引用次数: 0

Large language models: rheumatologists’ newest colleagues? 大型语言模型：风湿病学家的新同事？

IF 33.7 1区医学

Nature Reviews Rheumatology Pub Date : 2024-01-04 DOI: 10.1038/s41584-023-01070-9

Vincenzo Venerito, Latika Gupta

引用次数: 0

Epidemiology of Sjögren syndrome 斯约格伦综合征的流行病学。

IF 33.7 1区医学

Nature Reviews Rheumatology Pub Date : 2023-12-18 DOI: 10.1038/s41584-023-01057-6

Maxime Beydon, Sara McCoy, Yann Nguyen, Takayuki Sumida, Xavier Mariette, Raphaèle Seror

{"title":"Epidemiology of Sjögren syndrome","authors":"Maxime Beydon, Sara McCoy, Yann Nguyen, Takayuki Sumida, Xavier Mariette, Raphaèle Seror","doi":"10.1038/s41584-023-01057-6","DOIUrl":"10.1038/s41584-023-01057-6","url":null,"abstract":"Sjögren syndrome is a phenotypically varied autoimmune disorder that can occur alone in primary Sjögren syndrome or in association with other connective tissue diseases (CTDs), including rheumatoid arthritis, systemic lupus erythematosus (SLE) and systemic sclerosis (SSc). The estimation of the prevalence and incidence of Sjögren syndrome varies depending on diagnostic criteria and study design, making it difficult to estimate geographical and temporal trends. Nonetheless, disease phenotype is influenced by geographical origin, which is a risk factor for systemic activity. Whether mortality in primary Sjögren syndrome is increased compared with that of the general population is not yet known, but extra-glandular manifestations, in particular lymphomas, are clear risk factors for mortality. In CTDs associated with Sjögren syndrome, lymphoma risk seems higher than that of patients with CTD alone, and there is potentially lower disease activity in SLE with Sjögren syndrome and in SSc with Sjögren syndrome than in SLE or SSc alone. In this epidemiological Review, the authors summarize the available evidence relating to the prevalence, incidence, risk factors and mortality associated with the autoimmune disorder Sjögren syndrome, with or without the co-occurrence of other connective tissue diseases.","PeriodicalId":18810,"journal":{"name":"Nature Reviews Rheumatology","volume":null,"pages":null},"PeriodicalIF":33.7,"publicationDate":"2023-12-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138807549","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0